DGIdb - SORAFENIB Drug Record

SORAFENIB chembl:CHEMBL1336 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NEXAVAR
SORAFENIB
BAY-43-9006
N-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)-N'-(4-(2-(N-METHYLCARBAMOYL)-4-PYRIDYLOXY)PHENYL)UREA
SORAFENIBUM
NEXAVAR®
4-(4-((((4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)AMINO)CARBONYL)AMINO)PHENOXY)-N-METHYL-2-PYRIDINECARBOXAMIDE
BAY 43-9006
chemidplus:284461-73-0
pubchem.compound:216239
chembl:CHEMBL1336
drugbank:00398
rxcui:495881

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Drug Class	antineoplastic agents, protein kinase inhibitors
Year of Approval	2005
FDA Approval	Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma
Drug Class	Kinase Inhibitors

(11 More Sources)

Publications:

Handolias et al., 2010, Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT., Br. J. Cancer
Quintás-Cardama et al., 2008, Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib., Nat Clin Pract Oncol
Bisagni et al., 2009, Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma., J Thorac Oncol
Guo et al., 2007, Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor., Clin. Cancer Res.
Schirosi et al., 2012, Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors., Ann. Oncol.
Woodman et al., 2009, Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates., Mol. Cancer Ther.
Cascone et al., 2007, Combined targeted therapies in non-small cell lung cancer: a winner strategy?, Curr Opin Oncol
Koch et al., 2006, Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy?, Ann. N. Y. Acad. Sci.
Liu et al., 2006, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5., Cancer Res.
Guida et al., 2007, Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants., Clin. Cancer Res.
Lierman et al., 2007, The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors., Haematologica
Heinrich et al., 2012, Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors., Mol. Cancer Ther.
Dişel et al., 2011, Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation., Lung Cancer
Huynh et al., 2009, Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor., Mol. Cancer Ther.
Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
Allegra et al., 2014, A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib., J. Invest. Dermatol.
Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics
Escudier B et al., 2015, Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma., Clin Genitourin Cancer
Zheng YB et al., 2014, The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib., Med Oncol
Scartozzi M et al., 2014, VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study., Int J Cancer
Jain L et al., 2010, Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib., J Exp Clin Cancer Res
Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Antonescu et al., 2009, KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors., Cancer Res.
Schöffski et al., 2006, Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review., Ann. Oncol.
Adnane et al., 2006, Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature., Meth. Enzymol.
Veronese et al., 2006, Mechanisms of hypertension associated with BAY 43-9006., J. Clin. Oncol.
Rini, 2006, Sorafenib., Expert Opin Pharmacother
Lacouture et al., 2006, Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor., Clin. Exp. Dermatol.
Machado VA et al., 2015, Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors., Bioorg Med Chem
Li GB et al., 2015, LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors., Eur J Med Chem
Imielinski et al., 2014, Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma., J. Clin. Invest.
Doff et al., 1977, Root surface caries in the molar teeth of Rice rats. I. A method for quantitative scoring., J. Dent. Res.
Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
Unnithan et al., 2007, The role of targeted therapy in metastatic renal cell carcinoma., ScientificWorldJournal
Gollob, 2005, Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma., Clin Genitourin Cancer
Lu et al., 2010, Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway., J Surg Oncol
Gridelli et al., 2007, Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer., Oncologist
Huether et al., 2007, Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma., Biochem. Pharmacol.
Wilhelm et al., 2008, Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling., Mol. Cancer Ther.
Gollob et al., 2006, Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway., Semin. Oncol.
Smalley et al., 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations., Oncogene
Carlomagno et al., 2006, BAY 43-9006 inhibition of oncogenic RET mutants., J. Natl. Cancer Inst.
Wilhelm et al., 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis., Cancer Res.
Wilhelm et al., 2006, Discovery and development of sorafenib: a multikinase inhibitor for treating cancer., Nat Rev Drug Discov
Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
Paz-Ares et al., 2015, Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens., J Thorac Oncol
Dingemans et al., 2013, A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation., Clin. Cancer Res.
Wilson et al., 2016, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma., Clin. Cancer Res.
Lim et al., 2014, A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma., Clin. Cancer Res.
Papadimitrakopoulou et al., 2016, The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer., J. Clin. Oncol.
Auclair et al., 2007, Antitumor activity of sorafenib in FLT3-driven leukemic cells., Leukemia
Ravandi et al., 2013, Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation., Blood
Moreira et al., Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification., Case Rep Oncol
Albers et al., 2013, The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib., Leukemia
Kancha et al., 2007, Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations., Exp. Hematol.
Wang et al., 2012, MicroRNAs in liver disease., Gastroenterology
Piloto et al., 2007, Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways., Blood
Mathews et al., 2007, Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen., Haematologica
Zimmerman et al., 2013, Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia., Blood
Bagrintseva et al., 2004, Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells., Blood
Smith et al., 2013, Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD., Blood
Yamamoto et al., 2001, Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies., Blood
MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
Mardis et al., 2009, Recurring mutations found by sequencing an acute myeloid leukemia genome., N. Engl. J. Med.
Martelli et al., 2013, Mutational landscape of AML with normal cytogenetics: biological and clinical implications., Blood Rev.
Allen et al., 2013, The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia., Leukemia
Knapper et al., 2006, A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy., Blood
Man et al., 2012, Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation., Blood
Brown et al., 2005, FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression., Blood
Eisenhoffer et al., 2012, Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia., Nature
Clark et al., 2004, Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518., Blood
Smith et al., 2013, The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia., Am Soc Clin Oncol Educ Book
Jourdan et al., 2013, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia., Blood
Smith et al., 2012, Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia., Nature
Fischer et al., 2010, Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3., J. Clin. Oncol.
Baker et al., 2013, Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia., Clin. Cancer Res.
Gozgit et al., 2011, Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies., Mol. Cancer Ther.
Zhang et al., 2008, Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia., J. Natl. Cancer Inst.
Williams AB et al., 2013, Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors., Leukemia
Lam et al., 2010, Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer., J. Clin. Oncol.
Apsel B et al., 2008, Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases., Nat Chem Biol
Plaza-Menacho et al., 2007, Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting., J. Biol. Chem.
Flaherty, 2006, Chemotherapy and targeted therapy combinations in advanced melanoma., Clin. Cancer Res.
Kim et al., 2007, Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice., Mol. Cancer Ther.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Haluska et al., 2006, Therapeutic targets in melanoma: map kinase pathway., Curr Oncol Rep
Eisen et al., 2006, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis., Br. J. Cancer
Di Nicolantonio et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J. Clin. Oncol.
Nakaoku et al., 2014, Druggable oncogene fusions in invasive mucinous lung adenocarcinoma., Clin. Cancer Res.
Palanisamy et al., 2010, Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma., Nat. Med.
Bentivegna et al., 2008, Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)., Hum. Mutat.
Bardelli et al., 2012, The road to resistance: EGFR mutation and cetuximab., Nat. Med.
Tejpar et al., 2010, Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery., Oncologist
De Roock et al., 2009, Clinical biomarkers in oncology: focus on colorectal cancer., Mol Diagn Ther
Davies et al., 2002, Mutations of the BRAF gene in human cancer., Nature
De Roock et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol.
Maldonado et al., 2003, Determinants of BRAF mutations in primary melanomas., J. Natl. Cancer Inst.
Rizzo et al., 2010, Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?, Cancer Treat. Rev.
Hirschi et al., 2014, Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells., Mol. Cancer
Al-Marrawi et al., 2013, Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer., Cancer Biol. Ther.
Mangana et al., 2012, Sorafenib in melanoma., Expert Opin Investig Drugs
Casadei Gardini et al., 2016, Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report., BMC Cancer
Whittaker et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med
Selt F et al., 2017, Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing., Oncotarget
Reddy et al., 2006, Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma., Clin Genitourin Cancer
Lathia et al., 2006, Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics., Cancer Chemother. Pharmacol.
Strumberg, 2005, Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment., Drugs Today
Lee JH et al., 2013, Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma., Cancer
Ho et al., 2015, The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma., BMC Cancer
Boudou-Rouquette P et al., 2012, Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study., PLoS One
Casadei Gardini A et al., 2016, eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study., Oncotarget
Blumenschein et al., 2013, Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial., Clin. Cancer Res.
Diez-Cecilia E et al., 2015, Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway., Bioorg Med Chem Lett
Ullrich et al., 2011, BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines., Br. J. Haematol.
Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE
Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
Zheng et al., 2015, Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib., Onco Targets Ther
Chen KF et al., 2012, Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity., Eur J Med Chem
Ferrario et al., 2016, Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer., PLoS ONE
Herraez E et al., 2013, Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib., Hepatology
Poklepovic et al., 2016, Phase I study of pemetrexed with sorafenib in advanced solid tumors., Oncotarget
Bins S et al., 2016, Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity., Pharmacogenomics
Tsuchiya N et al., 2013, Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma., Anticancer Drugs
Arao et al., 2013, FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma., Hepatology
Hu C et al., 2018, Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma., J Hepatol

SORAFENIB FGF3

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22890726

Sources:
CIViC
SORAFENIB MAPK4

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB MAPK6

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB SLC15A2

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SORAFENIB MAPK7

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB ARAF

Interaction Score: 0.76

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Clinical Status case report

Pathway activation

Variant Effect gain-of-function

PMIDs:
24569458 72763 26619011

Sources:
MyCancerGenome DoCM CIViC PharmGKB OncoKB
SORAFENIB RAF1

Interaction Score: 0.6

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

PMIDs:
28362716 20124951 20812347 17296815 17266941 16757355 18852116 17272980 16890795 18794803

Sources:
MyCancerGenome TdgClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB
SORAFENIB PTPN6

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22871485

Sources:
DTC
SORAFENIB HMOX1

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26309414

Sources:
CIViC
SORAFENIB GALNT14

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31611591

Sources:
PharmGKB
SORAFENIB FLT3

Interaction Score: 0.36

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name Nexavar

PMIDs:
17205056 17229632 23613521 25848357 23392356 28362716 17889720 22504185 17047150 17606455 24046014 14604974 23430109 11290608 25157968 19657110 23261068 23783394 16857985 22368270 15374878 22504183 15256420 23714533 23321257 22504184 20733134 23969938 21482694 18230792 22858906

Sources:
TALC TdgClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC PharmGKB OncoKB
SORAFENIB KIT

Interaction Score: 0.34

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status case report

PMIDs:
20372153 18936790 19461405 17699867 22357254 19671763 17272980 17102120 17178882 17545544 17229632 22665524 20970876 19139124 25363205 24317392 28362716

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM CIViC PharmGKB TTD OncoKB
SORAFENIB ARID1A

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29113912

Sources:
CIViC
SORAFENIB BRAF

Interaction Score: 0.29

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Clinical Status preclinical

PMIDs:
20812347 16609060 17575107 11752352 16901402 16880785 18794803 19001320 24727320 20526349 18186519 25157968 22310681 20350999 19537845 12068308 20619739 14679157 21129611 26619011 28362716 24885690 23792568 22394203 23629727 27388325 20538618 28002790

Sources:
MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB
SORAFENIB KDR

Interaction Score: 0.15

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Evidence Type Actionable

Approval Status Preclinical

PMIDs:
28362716 25816720 25182707 24510746 20630084 20124951 19723655 16418310 16757355 16446323 16503817 16824050 26344591 25743214

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND CIViC MyCancerGenomeClinicalTrial PharmGKB TTD
SORAFENIB RET

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type thyroid medullary carcinoma

Response Type predicted – sensitive

Approval Status Phase II

PMIDs:
28362716 16507829 15466206 17016424 20368568 18849971 17664273

Sources:
DTC MyCancerGenome JAX-CKB CIViC PharmGKB
SORAFENIB PDGFRB

Interaction Score: 0.14

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Notes

PMIDs:
17619763 16425993 17545544 28362716

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB TTD
SORAFENIB UGT1A9

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28362716 22912756

Sources:
PharmGKB
SORAFENIB FLT4

Interaction Score: 0.11

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Notes

PMIDs:
16729906 16133532 16474853 16757355 17296815 28362716

Sources:
TALC DTC TdgClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB
SORAFENIB SLC22A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23532667

Sources:
PharmGKB
SORAFENIB FLT1

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16507829 15466206 17016424 28362716

Sources:
DTC MyCancerGenome MyCancerGenomeClinicalTrial PharmGKB
SORAFENIB NOS3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27058899

Sources:
PharmGKB
SORAFENIB DYRK3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MAPK13

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB MAPK11

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB SRPK1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB FGFR1

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Emerging

Approval Status Phase II

Response Type not applicable

PMIDs:
25900027 28362716 16507829 15466206 17016424

Sources:
JAX-CKB PharmGKB
SORAFENIB CYP2C8

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28362716

Sources:
PharmGKB
SORAFENIB VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24510746 22736425

Sources:
PharmGKB
SORAFENIB MAPK12

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB MAPK10

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB HIPK4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MAPK9

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB CSF1R

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Hodgkin's lymphoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
21517818

Sources:
DTC JAX-CKB
SORAFENIB HIPK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MAP3K20

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB PDGFRA

Interaction Score: 0.05

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
21482694

Sources:
DTC CIViC MyCancerGenomeClinicalTrial
SORAFENIB MKNK2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB KRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23629727 26743856 23224737 26307133 25294897 27480147 25363205

Sources:
JAX-CKB
SORAFENIB EPHA2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB CAMK2B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB IRAK1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MAPK3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB CDK8

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MAPK8

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB FGFR3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sorafenib + BEZ235

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

PMIDs:
26270481

Sources:
DTC JAX-CKB
SORAFENIB LIMK1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB NRAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Sorafenib

Indication/Tumor Type non-small cell lung carcinoma

Response Type sensitive

PMIDs:
23629727

Sources:
JAX-CKB
SORAFENIB CYP2B6

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28362716

Sources:
PharmGKB
SORAFENIB MAPK14

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
DTC PharmGKB
SORAFENIB EGFR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pimasertib + Sorafenib

Approval Status Preclinical - Cell line xenograft

Indication/Tumor Type non-small cell lung carcinoma

PMIDs:
23629727 26743856 24166906 26318998

Sources:
DTC JAX-CKB TTD
SORAFENIB AXL

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB SLCO1B1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27533851

Sources:
PharmGKB
SORAFENIB ABCC2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23237922

Sources:
PharmGKB
SORAFENIB MINK1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB PLK4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB SLK

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB TAOK1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB NTRK3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB RPS6KB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MAP4K5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB BLK

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB TNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22736425

Sources:
PharmGKB
SORAFENIB LYN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB NTRK2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB PIK3CA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23629727 25363205

Sources:
JAX-CKB
SORAFENIB AURKA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB PTEN

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Pemetrexed + Sorafenib

Indication/Tumor Type Advanced Solid Tumor

Response Type predicted – sensitive

PMIDs:
27213589

Sources:
JAX-CKB
SORAFENIB NTRK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Sorafenib

Indication/Tumor Type gastrointestinal stromal tumor

Response Type sensitive

PMIDs:
25363205

Sources:
JAX-CKB
SORAFENIB AURKB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB ABL1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB HIF1A

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25816720

Sources:
PharmGKB
SORAFENIB AKT1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Gemcitabine + Sorafenib

Indication/Tumor Type invasive bladder transitional cell carcinoma

Response Type predicted – resistant

PMIDs:
None found

Sources:
JAX-CKB
SORAFENIB ERBB2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Phase Ib/II

Indication/Tumor Type Her2-receptor negative breast cancer

combination therapy Sorafenib + Vinorelbine

PMIDs:
27992451

Sources:
JAX-CKB
SORAFENIB MAPK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20124951

Sources:
PharmGKB
SORAFENIB YES1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SORAFENIB CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28362716

Sources:
PharmGKB
SORAFENIB ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SORAFENIB CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28362716

Sources:
PharmGKB
SORAFENIB GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

MyCancerGenome: SORAFENIB
- Version: 20-Jun-2017
Alternate Names:

SORAFENIB Generic Name

NEXAVAR Trade Name

Drug Info:

Drug Class Kinase Inhibitors

FDA Approval Hepatocellular carcinoma, Renal cell carcinoma, Thyroid carcinoma

Publications:
TEND: SORAFENIB
- Version: 01-August-2011
Alternate Names:

SORAFENIB Primary Drug Name

Drug Info:

Year of Approval 2005

Drug Class antineoplastic agents, protein kinase inhibitors

Publications:
TdgClinicalTrial: SORAFENIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: SORAFENIB

Version: 02-September-2020

Alternate Names:

CHEMBL1336 ChEMBL Drug ID

Drug Info:

Publications:

Chen KF et al., 2012, Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity., Eur J Med Chem

Machado VA et al., 2015, Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors., Bioorg Med Chem

Li GB et al., 2015, LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors., Eur J Med Chem

JAX-CKB: Sorafenib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Antonescu et al., 2009, KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors., Cancer Res.

Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE

Whittaker et al., 2010, Gatekeeper mutations mediate resistance to BRAF-targeted therapies., Sci Transl Med

DoCM: SORAFENIB

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Schirosi et al., 2012, Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors., Ann. Oncol.

Guo et al., 2007, Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor., Clin. Cancer Res.

Bisagni et al., 2009, Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma., J Thorac Oncol

PharmGKB: sorafenib

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Imielinski et al., 2014, Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma., J. Clin. Invest.

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

Gong L et al., 2017, PharmGKB summary: sorafenib pathways., Pharmacogenet Genomics

CIViC: SORAFENIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Di Nicolantonio et al., 2008, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer., J. Clin. Oncol.

Smalley et al., 2009, CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations., Oncogene

Selt F et al., 2017, Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing., Oncotarget

TTD: Sorafenib
- Version: 2020.06.01
Alternate Names:

D0W5HK TTD Drug ID

Drug Info:

Publications:
TALC: SORAFENIB
- Version: 12-May-2016
Alternate Names:

SORAFENIB Primary Drug Name

SORAFENIB Drug Generic Name

NEXAVAR Drug Trade Name

Drug Info:

Publications:
OncoKB: Sorafenib
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1336
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: SORAFENIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: SORAFENIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
COSMIC: Sorafenib
- Version: 4-Sep-2020
Alternate Names:

Drug Info:

Publications:

Clinical Status	case report
Pathway	activation
Variant Effect	gain-of-function

Trial Name	Nexavar
Novel drug target	Established target
Clinical Status	preclinical

Indication/Tumor Type	thyroid medullary carcinoma
Response Type	predicted – sensitive
Approval Status	Phase II

Evidence Type	Emerging
Approval Status	Phase II
Response Type	not applicable

Indication/Tumor Type	Hodgkin's lymphoma
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Bevacizumab + Sorafenib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

combination therapy	Sorafenib + BEZ235
Indication/Tumor Type	urinary bladder cancer
Response Type	sensitive

combination therapy	Pimasertib + Sorafenib
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	sensitive

combination therapy	Pemetrexed + Sorafenib
Indication/Tumor Type	Advanced Solid Tumor
Response Type	predicted – sensitive

combination therapy	Cisplatin + Gemcitabine + Sorafenib
Indication/Tumor Type	invasive bladder transitional cell carcinoma
Response Type	predicted – resistant

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

antagonist (inhibitory)
inhibitor (inhibitory)

Approval Status	Phase Ib/II
Indication/Tumor Type	Her2-receptor negative breast cancer
combination therapy	Sorafenib + Vinorelbine

SORAFENIB	Primary Drug Name
SORAFENIB	Drug Generic Name
NEXAVAR	Drug Trade Name

SORAFENIB Drug Record

SORAFENIB chembl:CHEMBL1336 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22890726

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20124951

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Clinical Status case report Pathway activation Variant Effect gain-of-function

PMIDs: 24569458 72763 26619011

Sources: MyCancerGenome DoCM CIViC PharmGKB OncoKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Nexavar Novel drug target Established target

PMIDs: 28362716 20124951 20812347 17296815 17266941 16757355 18852116 17272980 16890795 18794803

Sources: MyCancerGenome TdgClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22871485

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26309414

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31611591

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name Nexavar

PMIDs: 17205056 17229632 23613521 25848357 23392356 28362716 17889720 22504185 17047150 17606455 24046014 14604974 23430109 11290608 25157968 19657110 23261068 23783394 16857985 22368270 15374878 22504183 15256420 23714533 23321257 22504184 20733134 23969938 21482694 18230792 22858906

Sources: TALC TdgClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC PharmGKB OncoKB

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status case report

PMIDs: 20372153 18936790 19461405 17699867 22357254 19671763 17272980 17102120 17178882 17545544 17229632 22665524 20970876 19139124 25363205 24317392 28362716

Sources: TALC MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM CIViC PharmGKB TTD OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29113912

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Nexavar Novel drug target Established target Clinical Status preclinical

PMIDs: 20812347 16609060 17575107 11752352 16901402 16880785 18794803 19001320 24727320 20526349 18186519 25157968 22310681 20350999 19537845 12068308 20619739 14679157 21129611 26619011 28362716 24885690 23792568 22394203 23629727 27388325 20538618 28002790

Sources: MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Notes Evidence Type Actionable Approval Status Preclinical

PMIDs: 28362716 25816720 25182707 24510746 20630084 20124951 19723655 16418310 16757355 16446323 16503817 16824050 26344591 25743214

Sources: TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND CIViC MyCancerGenomeClinicalTrial PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type thyroid medullary carcinoma Response Type predicted – sensitive Approval Status Phase II

PMIDs: 28362716 16507829 15466206 17016424 20368568 18849971 17664273

Sources: DTC MyCancerGenome JAX-CKB CIViC PharmGKB

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Nexavar Novel drug target Established target Notes

PMIDs: 17619763 16425993 17545544 28362716

Sources: TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28362716 22912756

Sources: PharmGKB

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info: Trial Name Nexavar Novel drug target Established target Notes

PMIDs: 16729906 16133532 16474853 16757355 17296815 28362716

Interaction Types & Directionality:

n/a

PMIDs:
22890726

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20124951

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Clinical Status case report

Pathway activation

Variant Effect gain-of-function

PMIDs:
24569458 72763 26619011

Sources:
MyCancerGenome DoCM CIViC PharmGKB OncoKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

PMIDs:
28362716 20124951 20812347 17296815 17266941 16757355 18852116 17272980 16890795 18794803

Sources:
MyCancerGenome TdgClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22871485

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
26309414

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
31611591

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name Nexavar

PMIDs:
17205056 17229632 23613521 25848357 23392356 28362716 17889720 22504185 17047150 17606455 24046014 14604974 23430109 11290608 25157968 19657110 23261068 23783394 16857985 22368270 15374878 22504183 15256420 23714533 23321257 22504184 20733134 23969938 21482694 18230792 22858906

Sources:
TALC TdgClinicalTrial JAX-CKB TEND DoCM COSMIC CIViC PharmGKB OncoKB

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status case report

PMIDs:
20372153 18936790 19461405 17699867 22357254 19671763 17272980 17102120 17178882 17545544 17229632 22665524 20970876 19139124 25363205 24317392 28362716

Sources:
TALC MyCancerGenome TdgClinicalTrial JAX-CKB TEND DoCM CIViC PharmGKB TTD OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
29113912

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Clinical Status preclinical

PMIDs:
20812347 16609060 17575107 11752352 16901402 16880785 18794803 19001320 24727320 20526349 18186519 25157968 22310681 20350999 19537845 12068308 20619739 14679157 21129611 26619011 28362716 24885690 23792568 22394203 23629727 27388325 20538618 28002790

Sources:
MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND DoCM CIViC MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Notes

Evidence Type Actionable

Approval Status Preclinical

PMIDs:
28362716 25816720 25182707 24510746 20630084 20124951 19723655 16418310 16757355 16446323 16503817 16824050 26344591 25743214

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial JAX-CKB TEND CIViC MyCancerGenomeClinicalTrial PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type thyroid medullary carcinoma

Response Type predicted – sensitive

Approval Status Phase II

PMIDs:
28362716 16507829 15466206 17016424 20368568 18849971 17664273

Sources:
DTC MyCancerGenome JAX-CKB CIViC PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Notes

PMIDs:
17619763 16425993 17545544 28362716

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
28362716 22912756

Sources:
PharmGKB

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Trial Name Nexavar

Novel drug target Established target

Notes

PMIDs:
16729906 16133532 16474853 16757355 17296815 28362716

Sources:
TALC DTC TdgClinicalTrial TEND MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23532667

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16507829 15466206 17016424 28362716

Sources:
DTC MyCancerGenome MyCancerGenomeClinicalTrial PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27058899

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
20124951